Singh, SanjayGumbo, TawandaAlffenaar, Jan-WillemBoorgula, Gunavanthi D.Shankar, PremThomas, Tania A.Dheda, KeertanMalinga, Lesibana AnthonyRaj, PrithviAryal, SantoshSrivastava, Shashikant2024-05-272023-12Singh, S., Gumbo, T., Alffenaar, J.-W. et al. 2023, 'Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen', International Journal of Antimicrobial Agents, vol. 62, no. 6, art. 106968, pp. 1-8, doi : 10.1016/j.ijantimicag.2023.106968.0924-8579 (print)1872-7913 (online)10.1016/j.ijantimicag.2023.106968http://hdl.handle.net/2263/96243DATA AVAILABILITY STATEMENT : Upon a reasonable request, the raw data for the results presented in the manuscript are available from the corresponding author.Please read abstract in the article.en© 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved. Notice : this is the author’s version of a work that was accepted for publication in International Journal of Antimicrobial Agents. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. A definitive version was subsequently published in International Journal of Antimicrobial Agents, vol. 62, no. 6, art. 106968, pp. 1-8, doi : 10.1016/j.ijantimicag.2023.106968.Beta-lactamsPharmacokineticsPharmacodynamicsTuberculosis (TB)β-lactamase inhibitors (BLIs)Bedaquiline-pretonamid-linezolid (BPaL)Hollow fiber model systemMultidrug-resistant tuberculosis (MDR-TB)Mycobacterium tuberculosis (MTB)SDG-03: Good health and well-beingPostprint Article